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The number of promising viral targets and classes of compounds with substantial antiherpetic 
properties considerably increased during the last decade. However, no new effective and low-
toxicity clinical drugs against both wild-type viruses and drug-resistant strains have appeared. 
This situation makes the search for new antiherpetic drugs and their new targets a high prior-
ity task. Aim. To study the effect of fluorinated N-alkylthioamides on the herpes simplex virus-1 
(HSV-1). Methods. The influence of these compounds on the multiplicity and infectivity of 
HSV-1 was determined by the MTT-assay, virucidal assay, adsorption and penetration assays, 
PCR and infectious virus yield reduction assay. Results. The 10S-23 and 10S-24 compounds 
prevented the adsorption and penetration of HSV-1 into cells by up to 26%. HSV-1 DNA 
replication was moderately inhibited by the 10S-24 compound (up to 39 %). The 10S-23 and 
10S-24 compounds  in concentrations of 100 – 33 μg/ml reduced HSV-1 virus production by 
70–99% and >99%, respectively. Conclusion. The 10S-24 compound may be used as a 
therapeutic agent to reduce the penetration, replication and translation of HSV-1.
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Introduction 
The character of diseases caused by Alpha her­
pes viruses has changed over the last decade. 
The severity of disease and the frequency of 
acyclovir resistance increased with an increase 
in the number of immunocompromised patients. 
Most modern drugs for the treatment of her-
petic infections are based on the use of modified 
nucleosides or their prodrugs [1]. Noteworthy, 
the drugs do not save the patient from the recur-
rent character of the disease, and their prolonged 
administration can cause the emergence of re-
sistant virus strains. Moreover, to date, none of 
the currently approved antiviral drugs has been 
able to eliminate an established latent infection 
[2, 3]. Many of the newer experimental agents 
target the essential processes unique to herpes-
virus replication and, therefore, are potentially 
highly selective [4].
ISSN 1993­6842 (on­line); ISSN 0233­7657 (print) 
Biopolymers and Cell. 2018. Vol. 34. N 1. P 49–58 
doi: http://dx.doi.org/10.7124/bc.000970
50
L. Biliavska, Y. Pankivska, O. Povnitsa et al.
Due to synthetic accessibility and high 
chemical and biological stability, the fluorine 
containing compounds are popular building-
blocks from the standpoint of medicinal che-
mis try. Because of similarity in size to hydro-
gen, it has been shown that microorganisms or 
enzymes often do not recognize the difference 
between a natural substrate and its analogue 
wherein a C – H bond of the substrate is re-
placed with a C – F bond. This observation is 
a basis of what is regarded as the “mimic ef-
fect” of fluorine for hydrogen. This strongly 
suggests that not only single fluorine displace-
ment but also various fluorine-substitution 
patterns in the substrate analogues or inhibitors 
could be adapted to biological systems in a 
molecular – recognition mode similar to that 
of the natural substrates [5]. The presence of 
a fluorine atom in the molecule influences the 
chemical, physical and biological properties 
of compounds. A fluorine atom is involved in 
many biochemical reactions as activator and 
inhibitor of enzymes, of the metabolism and 
thyroid hormone, the synthesis of nucleic ac-
ids, proteins and lipids. Thus, fluorinated ana-
logs of biological molecules are useful tools 
to study and modify the function of biological 
systems. It is known that the insertion of fluo-
rine atoms in the molecule of biologically 
active compounds can affect not only their 
pharmacokinetic properties, but also the allo-
cation in the tissues, path and metabolic rate 
of the fluorine analogue and the pharmacody-
namics and toxi cology [6, 7]. All these factors 
play a key role in the creation of the drugs 
based on nucleoside and non-nucleoside ana-
logues and cause a considerable interest to the 
medicinal chemistry of fluorine compo-
unds [8, 9] 
In the present study, the effect of new fluori-
nated derivatives of amino acids on the herpes 
simplex virus-1 (HSV-1) multiplicity was stu died. 
Materials and Methods
Virus and cells
The Syrian hamster kidney fibroblasts 
(BHK-21) and the strain US of herpes simplex 
virus type 1 (HSV-1/US) were used in this 
study. The cells and virus were cultured ac-
cording to standard methods.
Tested substances
The general characteristics of the fluorinated 
derivatives of amino acids (fluorinated N-alkyl-
thioamides) were shown by Pikun et al [10]. The 
compounds are classified according to the type 
of amino acid, its configurations, the number of 
fluorine atoms and the position of the fluorine 
substitution (2’, 3’, or both) (Fig. 1). 
Cellular toxicity 
Cellular toxicity of compounds was tested in 
vitro according to a cell viability assay previ-
ously reported [11]. Monolayers of BHK 
21 cells in 96-multiwell plates were incubated 
with the compounds in concentration of 1000 – 
15.6 μg/ml for 48 h, then 20 μl of a 5 mg/ml 
solution of MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide, 
Sigma) were added to the medium. The plates 
were read using an automatic plate reader 
Multiskan FC (Thermo Scientific, USA) at 
538 nm test wavelength. 
Antiviral Assay 
We used a modification of an MTT-assay 
developed for screening anti-HSV compo-
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unds [12]. 50 µl of virus suspension (a mul-
tiplicity of infection (MOI) of 0.5 and 0.05) 
were added to BHK 21 cells. In 2 h, an un-
absorbed virus was aspirated and 200 µl of 
serial three-fold drug-containing medium 
were added to each well, and incubated at 
37˚C and 5% CO2 for 2 days. The percent of 
protection was calculated by the following 
formula: 
(OD exp.) – (OD virus control)
× 100%
(OD cell control) – (OD virus control)
where (OD exp.), (OD virus control), (OD cell 
control) indicate the absorbencies of the tested 
sample, the virus control and the cell control, 
respectively. 
Plaque reduction assay 
The BHK 21 cells monolayer was infected 
with 0.02 MOI of HSV-1 in the absence or 
presence of the substances. After 2 h of adsorp-
tion, the cell monolayer was covered with 
overlay medium. The infected cell monolayer 
was fixed and stained with 1% Crystal Violet 
in 20% ethanol. The antiviral activity of sub-
stances was determined by the following for-
mula [13]:
Percentage 
inhibition = [1 – 
number of 
plaque (tested)
] × 100%
number of 
plaque (control)
Virucidal assay
100 µL of 2X compounds in a supportive me-
dium (66, 22 and 7.4 μg/ml) were mixed with 
100 µL of 2X HSV-1 in microfuge tubes and 
incubated at 37°C for 30 min and 2 h. Then, 
50 µL of each mixture were added to a separate 
well on a 96-well plate containing BHK 
21 cells. The plates were incubated at 37°C 
and 5% CO2 for 2 h. The cells were washed 
Fig. 1. Structure of compounds and 
scheme of their synthesis 
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with PBS (рН=7.4) and 200 µl of overlay 
medium were added [14, 15]. The MOI of 
HSV-1 after dilution was 0.03. Plaques were 
counted as described above. 
Attachment assay
The attachment assay described by De Logu 
et al. [16, 17] was used in this study with a 
minor modification. Briefly, BHK 21 cell 
monolayer was pre-chilled at 4°C for 1 h and 
then infected with 0.03 MOI HSV-1 in the 
absence or presence of serial dilution com-
pounds. After 3 h of incubation at 4°C, the cell 
monolayer was washed with PBS three times 
and overlaid with medium containing 0.06% 
agarose. Plaques were counted as described 
above. 
Viral Penetration Assay
The assay of HSV-1 penetration into BHK 21 
cells was performed according to the pub-
lished procedures, with minor modifications 
[18]. A BHK 21 cell monolayer was pre-
chilled at 4°C for 1 h, infected with 0.3 MOI 
HSV-1 and incubated at 4°C for further 3 h 
to allow the attachment of HSV-1. After in-
cubation, 25 µL of 2x concentration of com-
pounds were added. Infected cell monolayer 
was then incubated at 37°C to maximize the 
penetration of viruses. In 10 min, the in-
fected cell monolayer was treated with PBS 
at pH 3 for 1 min to inactivate non-penetrat-
ed virus. PBS at pH 11 was then immedi-
ately added to neutralize acidic PBS. The 
neutral PBS was removed and the cell mono-
layer was covered with overlay medium. After 
further 48 h incubation, the cell monolayer 
was fixed and stained. Plaques were counted 
as described above.
Real­time PCR analyses 
Real-time PCR was utilized to derive the total 
number of viral genomes within the lysate. 
Lysates were collected at 48 h p.i., and 200 µL 
of each suspension were used for the extraction 
of viral DNA. Viral DNA was extracted using 
innuPREPVirus DNA Kit (Analityk Jena AC, 
Germany) according to the manufacturer’s 
instructions. PCR tests were performed with 
“AmpliSens®HSV-screen-FL» (AmpliSens, 
Russia) according to the manufacturer’s rec-
ommendations. The Thermocycler qTOW-
ER 2.2 (Analytic Jena, Germany) was used. 
Infectious virus yield reduction assay
Monolayer of BHK 21 cells was infected by 
adsorption of HSV-1 at a MOI of 0.02 and 0.2 
for 2 h at 37°C and 5% CO2. The compounds 
in concentrations ranging between 100 and 
3.7 μg/ml were added immediately after ad-
sorption. In 48h after virus inoculation, the 
cells in culture medium were lysed by freezing 
and thawing (three times). Ten-fold serial dilu-
tions of HSV-1 and virus-treated extracts of 
HSV-1 were prepared prior to the infection. 
The number of plaque-forming units was de-
termined and a decrease of virus titer was 
calculated [19]:
Percentage inhibition 
of virus reproduction = (1 –Т/С) × 100%
where T is the compounds-treated viral titers 
and C is the control viral titers.
Results and Discussion
The first stage of the antiviral assay is neces-
sary to determine the concentrations of the 
compounds that are not toxic to the cells. 
According to the MTT test results, the CC50 
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values of 10S-20, 10S-23 and 10S-24 for BHK 
21 cells were 1731.8, 1000.7 and 1004.2 µg/
ml, respectively (Table 1). The compounds 
10S-20 in concentration of 1500 µg/ml, 10S-23 
and 10S-24 in concentration of 500 µg/ml 
exhibited a weak cytotoxic effect, and 96% of 
cells survived (data not shown). The com-
pounds 10S-21 and 10S-22 demonstrated CC50 
values equal to 510.3 and 304.5 µg/ml, respec-
tively. 
The most perspective compounds in the 
concentration range used to assess their activ-
ity did not induce any visible changes in the 
BHK 21 cell morphology or density. The de-
rivatives of amino acids exhibited in vitro 
anti-HSV-1 activities at different magnitudes 
of potency; the EC50 for 5 tested compounds 
was in the range of 15 – 247 µg/ml, their in-
hibitory effect on HSV-1 multiplication was 
MOI dependent (Table 1). ACV was used as a 
reference compound. The 10S-23 and 10S-24 
compounds showed potent anti-HSV-1 activ-
ity, their EC50 increased from 47.9 to 70.9 µg/
ml and 15.4 to 35.0 µg/ml, respectively, where-
as MOI increased from 0.05 to 0.5. Other 3 
compounds were either mild or weakly active 
to suppress the HSV-1 infection, their 
EC50 102 – 247 µg/ml. 
The selectivity index (SI) for the anti-
HSV-1 assay was in the range of 2 - 67. SIs of 
10S-23 and 10S-24 for MOI 0.05 were 14 and 
29, for 0.5 were 21 and 67, respectively. Based 
on these results, 10S-23 and 10S-24 were se-
lected for further research on their antiviral 
activity and targets of action.
The antiviral effects of compounds against 
HSV-1 infection were evaluated by [the] 
plaque reduction assay. The results revealed 
that both 10S-23 and 10S-24 inhibit HSV-1 
and their plaque formation in a dose-dependent 
manner (Fig. 2).
10S-24 at concentrations of 33 – 150 μg/ml 
inhibited the HSV-1 plaque formation by 70 – 
95 %, whereas 10S-23 significantly inhibited 
the plaque formation at higher concentrations 
(100 and 150 μg/ml).
Herpes virus reproduction is characterized 
by a complex sequence of different steps at 
which antiviral agents might interfere. The 
need for additional anti-herpetic drugs, the 
Table 1. Anti-HSV-1 activity, cell cytotoxic effect and selectivity index of fluorine-containing derivatives of 
amino acids for BHK 21cellsa
Compound
Antiviral activity, EC50b (µg/ml) Cell cytotoxic effect, CC50b, 
(µg/ml)
Selectivity index (SI)
moi 0.05 moi 0.5 moi 0.05 moi 0.5
10S-20 –* 247.2±5.2 1731.8±36.1 –* 7
10S-21 102.9±3.4 125.4±3.7 510.3±7.5 5 4
10S-22 131.3±3.8 175.1±4.4 304.5±5.8 2 2
10S-23 47.9±2.3 70.9±2.8 1000.7±20.5 21 14
10S-24 15.4±1.3 35.0±2.0 1004.2±10.8 67 29
Aciclovir 5.6±0.8 7.7±0.9 1006.0±14.3 178 129
a – Antiviral activity and cell cytotoxic effect were determined by MTT assay. b – Values represent the mean ± S.D. for three 
independent experiments. SI is the ratio of CC50 to EC50. EC50 the concentration, which corresponded to 50% inhibition of HSV-1 
multiplication. CC50 was the concentration that showed 50% cellular cytotoxic effect. –* – no anti-HSV-1 activity.
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mechanisms of action of which differ from that 
of ACV, remains a high priority in the antiviral 
drug research today. For example, polyamino-
acid-based derivatives, such as poly-L-lysine 
and poly-L-arginine, appear to act primarily 
by inhibiting early stages of virus replication, 
prevent HSV-1 binding to cellular receptors 
and consequently internalization of the virus 
into the cells [2, 20].  
To determine a stage of the HSV-1 infection 
inhibited by the derivatives of L-phenylalanine, 
the virus and cell were treated with the com-
pounds at various times before and after the 
HSV-1 infections. The fluorinated derivatives 
of amino acids have been reported to possess 
a variety of biological activities, including 
antiviral, antimicrobial, antitumor, antioxidant, 
enzyme-inhibiting, etc. [5, 9]. For antiviral 
activity, it is believed that the inhibitory effect 
is caused by binding of the derivatives of ami-
no acids to the protein coat of the virus and/or 
the host cell membrane. The virus adsorption 
Table 2. Dependence of anti-HSV-1 activity of fluorine-containing derivatives of L-phenylalanine on 
treatment schedule
Concentration 
(μg/ml)
Compounds present:
30 min. before adsorption 2 h before adsorption During adsorption During penetration
% inhibition
10S-23
33 2.91±0.57 24.02±1.63 21.24±1.54 18.54±1.43
11 2.94±0.57 2.01±0.47 0 12.36±1.17
3.7 2.96±0.58 0 0 0
10S-24
33 0 8.84±1.03 6.18±0.87 25.92±1.70
11 0 6.95±0.92 4.08±0.67 2.57±0.53
3.7 0 4.91±0.77 2.03±0.48 0
Each point represents the mean ± S.D. for three independent experiments. Significant difference between tested sample and 
control (P < 0.05).
Fig. 2. Plaque reduction assay of 
HSV-1 exposed to different concen-
trations of fluorinated derivatives of 
L-phenylalanine (percentage of inhi­
bition of treated HSV­1 relative to 
the control).
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and eventual virus penetration are arrested. 
The compounds affected the virus penetration 
process possibly through detaching the virus 
already bound to the cell, perhaps by the dis-
turbance of viral glycoproteins [1].
Table 2 shows that different inhibitory ef-
fects were observed when the compounds were 
added 30 min and 2 h before adsorption, dur-
ing virus adsorption and penetration. 
The 10S-24 compound had no significant 
direct virucidal effect on HSV-1 even at the 
concentration of 33 µg/ml or lower, whereas 
10S-23 reduced the HSV-1 infectivity by 24% 
when added to virus 2 h before adsorption. 
The results indicate that the 10S-23 and 
10S-24 compounds at higher concentrations 
showed a reducing effect on the viral adsorp-
tion and penetration (Table. 2). It was found 
that 10S-23 in concentrations of 33 µg/ml 
reduced the HSV-1 attachment to cells by 21%. 
Our studies revealed that 10S-23 and 10S-24 
in concentration of 33 μg/ml were able to 
prevent the penetration of HSV-1 into cells by 
18.5 and 25.9 %, respectively.
Based on previously reported findings, as 
well as on our data, and in view of the chem-
ical nature of compounds, we hypothesized 
that 10S-23 and 10S-24 might prevent the 
formation of a full and infectivity virus prog-
eny. Phenylalanine residues are aromatic and 
hydrophobic amino acids known to be in-
volved in protein-protein interactions and to 
play an important role in the virus assembly 
and a critical regulatory function in the infec-
tious virus production [21]. The antiviral activ-
ity assessed via real-time PCR and infectious 
virus yield reduction assay demonstrated the 
inhibitory effect of these compounds at the late 
stage of the virus reproduction. 
As shown in Fig. 3, in the presence of 10S-
24 in high concentrations, the HSV-1 DNA 
replication was moderately inhibited and the 
viral DNA copy number reduced to 73 and 
61% of the number of viral control, for MOI 
0.02 and 0.2, respectively. 10S-23 irrespective 
of the multiplicity of infection of the virus 
could not fundamentally suppress DNA syn-
thesis of HSV-1 in the BHK-21 cells, DNA 
replication of virus decreased by 5 – 18% only.
The compounds were added to a cell at the 
end of the virus adsorption period (2 h after 
infection), a significant delay in the growth 
of HSV-1 was observed, and a much lower 
yield of infectious virus was also obtained 
(Table. 3).
It was found that at the concentration of 
100 – 33μg/ml, the compound 10S-24 regard-
less of multiplicity of infection considerably 
reduces (by >99%) the titer of virus obtained 
de novo, whereas for all analyzed concentra-
tions of the compound 10S-23 a decrease of 
virus titer by 83 – 98% and 68 – 99% was 
observed for MOI 0.2 and 0.02, respectively. 
Interestingly, the anti-HSV activity of 
10S-21, 10S-23 and 10S-24, containing 
L-phe ny la lanine, was greater in comparison 
to 10S-20 and 10S-22, which contain other 
amino acids in the molecules. However, only 
sodium salts of L-phenylalanine demonstra-
ted potent anti-viral activity. Noteworthy, the 
low virus-inhibitory action of 10S-23 com-
pared with 10S-24 can be attributed to the 
absence of a tetrafluoropropanethioyl group 
in the structure. This suggests that the anti-
HSV activity of this group of the compounds 
depends not only on amino acid but also on 
the number of the fluorine atoms in the mo-
le cule.
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Table 3. Effect of fluorinated sodium salts of L-phenylalanine on HSV-1 infectivity 
Concentration of 
compound, (µg/ml)
HSV-1 at moi 0.02 HSV-1 at moi 0.2
Virus titer PFU/ml % of inhibition Virus titer PFU/ml % of inhibition
10S-23
100 4,0 х105 70,87 8,0 х105 98,03
50 2,7 х104 98,06 11,0 х106 97,31
33 1,4 х104 99,00 6,7 х106 83,45
11 1,6 х105 88,35 6,9 х106 83,05
3,4 4,4 х105 67,96 6,9 х106 83,05
10S-24
100 1,3 х103 99,90 8,0 х104 99,80
50 1,2 х104 99,13 6,7 х104 99,84
33 6,7 х103 99,51 1,7 х104 99,57
11 1,1 х104 99,22 9,2 х105 97,73
3,4 1,2 х105 91,46 2,5 х106 93,76
Сontrol of virus 1,4х106 – 4,1х107 –
Conclusion
Taken together, our results showed that 10S-
23 and 10S-24 in non-toxic concentrations 
possess the anti-HSV activity, which is real-
ized via multiple mechanisms. The compound 
10S-23 reduces the viral adsorption, penetra-
tion and yield of virus particles. The com-
pound 10S-24 blocks the viral penetration 
into cells, inhibits the viral DNA replication 
and infectivity of viral progeny, which is 
probably caused by decreasing protein syn-
thesis or capsid assembly. Taking into account 
the promising antiherpetic activity of sodium 
salts of L-phe n ylalanine herein reported, fur-
ther investigation is needed to explore the 
antiviral mechanism of these compounds in 
detail. 
Funding
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Fig. 3. Effect of sodium salts of L-phe-
nylalanine on HSV-1 DNA synthesis
For the DNA synthesis assay, BHK-21 
cells were treated with 10S-23 and 10S-
24 compounds and ACV (3.4 – 33µg/
ml) after HSV-1 adsorption (MOI of 
0.02 and 0.2), at 48 h p.i., the infected 
cultures were harvested and extracted 
viral DNA. Real-time PCR was con-
ducted. Data represents the mean±S.D. 
of three independent experiments with 
virus control (100%). p<0.05.
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Вплив фторованих N-алкілтіоамідів 
на репродукцію ВПГ-1
Л. О. Білявська, Ю. Б. Паньківська, 
О. Ю. Повниця, Н. В. Пікун, Ю. Г. Шермолович, 
С. Д. Загородня
Протягом останнього десятиліття збільшилася кількість 
перспективних вірусних мішеней і класів сполук із зна-
чними протигерпетичними властивостями. Однак, ще 
не з’явилися нові ефективні низькотоксичні препарати, 
які були б активні як проти вірусів дикого типу, так і 
проти резистентних штамів. Мета. Дослідити вплив 
фторовмісних N-алкілтіоамідів на репродукцію вірусу 
простого герпесу-1 (ВПГ-1). Методи. З використанням 
МТТ-аналізу ПЛР та методу редукції кількості бляшок 
досліджували віруліцидну дію сполук та їхній вплив на 
адсорбцію, проникнення вірусу, реплікацію вірусної 
ДНК та інфекційні титри. Результати. Показано, що 
сполуки 10S-23 та 10S-24 на 26% запобігали адсорбції 
та проникненню ВПГ-1 в клітини. Сполука 10S-24 до 
39 % пригнічувала реплікацію ВПГ-1. Встановлено, що 
при концентрації 33–100 мкг/мл 10S-23 та 10S-24 зни-
жують титр вірусу, синтезованого de novo, на 70–99 % 
та > 99% відповідно. Висновок. Отримані дані свідчать 
про перспективність використання сполуки 10S-24 як 
терапевтичного засобу для зниження проникнення ВПГ-
1 до клітин, його реплікації та трансляції.
К л юч ов і  с л ов а: вірус простого герпесу, фторовані 
N-aлкілтіоаміди, противірусна активність.
Влияние фторированных N-алкилтиоамидов 
на репродукцию ВПГ-1
Л. А. Белявская, Ю. Б. Паньковская, 
О. Ю. Повница, Н. В. Пикун, Ю. Г. Шермолович, 
С. Д. Загородняя
В течении последнего десятилетия увеличилось коли-
чество перспективных вирусных мишеней и классов 
соединений со значительными противогерпетически-
ми свойствами. Однако еще не появились новые эф-
фективные и низкотоксичные препараты которые ак-
тивны как против вирусов дикого типа, так и против 
резистентных штаммов. Цель. Исследовать влияние 
фторсодержащих N-алкилтиоамидов на репродукцию 
вируса простого герпеса первого типа (ВПГ-1). 
Методы. С использованием МТТ-анализа, ПЦР и 
метода редукции количества бляшок проводили иссле-
дование вирулицидности и действия соединений на 
адсорбцию, проникновение, репликацию и инфекци-
онные титры вируса. Результаты. Показано, на что 
соединения 10S-23 и 10S-24 на 26 % предотвращали 
адсорбцию и проникновение ВПГ-1 в клетки. Сое ди-
не ние 10S-24 способно до 39 % подавлять репликацию 
ВПГ-1. Установлено, что при концентрации 33–
100 мкг/мл 10S-23 и 10S-24 снижали титр вируса, 
синтезированного de novo, на 70–99 % и > 99 %, соот-
ветственно. Вывод. Полученные данные свидетель-
ствуют о перспективности использования соединения 
10S-24 в качестве терапевтического средства для сни-
жения проникновения ВПГ-1 в клетки, его репликации 
и трансляции.
К л юч е в ы е  с л ов а: вирус простого герпеса, фто-
рированные N-aлкилтиоамиды, противовирусная ак-
тивность.
Received 30.06.2017
